Performance of laboratories in antimicrobial susceptibility testing of MB-16-6
| Antibiotics | MIC | Antibiotics | Disk | ||||||
|---|---|---|---|---|---|---|---|---|---|
| S | I | R | IND | S | I | R | IND | ||
| CLSI group A | |||||||||
| Ampicillin | 181 | 1 | 1 | Ampicillin | 14 | 1 | |||
| Penicillin G | 196 | 1 | Penicillin G | 14 | 3 | ||||
| Clindamycin | 206 | 2 | Clindamycin | 23 | 3 | ||||
| Erythromycin | 189 | 2 | Erythromycin | 22 | 2 | ||||
| Other CLSI groups | |||||||||
| Azithromycin | 1 | Cefepime | 2 | ||||||
| Cefepime | 24 | Cefotaxime | 14 | ||||||
| Cefotaxime | 164 | Ceftriaxone | 7 | 1 | |||||
| Ceftriaxone | 133 | Chloramphenicol | 7 | ||||||
| Chloramphenicol | 14 | Levofloxacin | 5 | 2 | |||||
| Daptomycin | 16 | Linezolid | 5 | ||||||
| Levofloxacin | 164 | Ofloxacin | 2 | ||||||
| Linezolid | 152 | Tetracycline | 5 | ||||||
| Meropenem | 3 | Vancomycin | 21 | 5 | |||||
| Quinupristin/Dalfopristin | 11 | ||||||||
| Tetracycline | 4 | 48 | |||||||
| Vancomycin | 214 | ||||||||
| Unacceptable | |||||||||
| Ceftizoxime | 1 | Bacitracin | 1 | ||||||
| Ciprofloxacin | 2 | Cefoperazone/Sulbactam | 1 | ||||||
| Imipenem | 2 | Cefoxitin | 1 | ||||||
| Norfloxacin | 1 | Ceftazidime | 1 | ||||||
| Piperacillin | 1 | Ciprofloxacin | 3 | 1 | |||||
| Piperacillin/Tazobactam | 1 | Gentamicin | 1 | 1 | |||||
| Teicoplanin | 1 | Minocycline | 1 | ||||||
| Trimethoprim/Sulfamethoxa | 10 | Netilmicin | 1 | ||||||
| Oxacillin | 2 | 1 | 1 | ||||||
| Oxacillin (Cefoxitin) | 1 | ||||||||
| Rifampicin | 1 | ||||||||
| Teicoplanin | 3 | ||||||||
| Trimethoprim/Sulfamethoxa | 1 | 1 | |||||||
| IND | |||||||||
| Ofloxacin | 1 | Amoxicillin/Clavulanic acid | 1 | ||||||
| Ampicillin/Sulbactam | 1 | ||||||||
| Cefazolin | 2 | ||||||||
| Cephalothin | 2 | ||||||||
| Imipenem | 2 | ||||||||
Abbreviations: MIC, minimum inhibitory concentration; S, susceptible; I, intermediate; R, resistance; IND, indeterminate; CLSI, Clinical and Laboratory Standards Institute.